These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31702643)

  • 1. Efficacy and safety of HT080 for lower urinary tract symptoms associated with benign prostatic hyperplasia: A study protocol for a randomized, double-blind, placebo-controlled trial.
    Song J; Lee SH; Kim H
    Medicine (Baltimore); 2019 Nov; 98(45):e17848. PubMed ID: 31702643
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kim M; Tran P; Yin J; Song J; Kim H
    Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serenoa repens for benign prostatic hyperplasia.
    Tacklind J; Macdonald R; Rutks I; Stanke JU; Wilt TJ
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD001423. PubMed ID: 23235581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
    Ye Z; Huang J; Zhou L; Chen S; Wang Z; Ma L; Wang D; Wang G; Wang S; Liang C; Qiu S; Gu X; Liu J; Weng Z; Wu C; Wei Q; Xie L; Wu W; Cheng Y; Hu J; Wang Z; Zeng X
    Urology; 2019 Jul; 129():172-179. PubMed ID: 30880074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
    Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
    Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.
    Oelke M; Wagg A; Takita Y; Büttner H; Viktrup L
    BJU Int; 2017 May; 119(5):793-803. PubMed ID: 27988986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
    MacDonald R; Tacklind JW; Rutks I; Wilt TJ
    BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
    Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
    J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)].
    Kogan MI; Avadieva NE; Gevorkyan LS; Loginov YA; Metelkin AM; Mitin AA; Patrikeev AA
    Urologiia; 2023 May; (2):32-40. PubMed ID: 37401702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
    Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
    BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study.
    Singh I; Tk A; Gupta S
    Int J Clin Pract; 2020 Aug; 74(8):e13530. PubMed ID: 32542854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.